Echo IQ Limited Issues 1.5 Million Shares After Unlisted Options Exercised, Complies with Section 708A

Echo IQ’s AI-Driven Cardiology Technology Focus

Echo IQ Limited operates as an AI and medical technology company dedicated to enhancing decision-making in cardiology. Headquartered in Sydney, Australia, the company leverages artificial intelligence and proprietary software to provide cardiology solutions that assist medical professionals in making informed clinical decisions. Its technology platform utilises advanced computational methods and machine learning to analyse cardiac data and deliver actionable insights.

Located at Level 11, 66 Clarence Street, Sydney, NSW 2000, Echo IQ is positioned within Australia’s expanding medical technology and digital health sector. The company’s business model focuses on developing and deploying AI-integrated software solutions tailored to cardiology. Listed on the Australian Securities Exchange under ticker EIQ, Echo IQ offers investors exposure to the medical technology and AI sectors.

Share Issuance After Unlisted Options Exercise

On 22 July 2026, Echo IQ completed the issuance of 1.5 million fully paid ordinary shares following the exercise of unlisted options by shareholders. These options carried a strike price of $0.35 per share and expire on 20 June 2028. This capital event increases the company’s ordinary shares outstanding, expanding its equity base. The issuance was conducted without a prospectus or product disclosure document, relying on regulatory relief under Australian corporations law.

The newly issued shares are now quoted on the Australian Securities Exchange and form part of the company’s ordinary share class, carrying identical rights and obligations as existing shares. While the immediate share price impact is not publicly disclosed, the exercise signals option holders’ confidence in Echo IQ’s prospects and represents capital raising that dilutes existing shareholders per share but strengthens the overall equity base for operations and strategic growth.

Regulatory Compliance and Section 708A Cleansing Notice

Echo IQ issued a cleansing notice on 22 July 2026 pursuant to Section 708A(5)(e) of the Corporations Act 2001 (Cth). This regulatory mechanism notifies the market that shares were issued without disclosure documents, relying on relief under Section 708A(5). The notice confirms all procedural and substantive requirements under Australian corporations law were met, enabling free trading of the shares without a prospectus requirement on resale.

The cleansing notice confirms Echo IQ’s compliance with Chapter 2M of the Corporations Act 2001, covering continuous disclosure obligations for listed companies, and Sections 674 and 674A relating to financial reporting and lodgement with ASIC. Importantly, the company stated no excluded information exists as of 22 July 2026 under Sections 708A(7) and (8), meaning no undisclosed information likely to materially affect the securities’ price or value.

Section 708A Relief Facilitates Share Issuance Without Disclosure

Section 708A(5) of the Corporations Act provides relief from prospectus requirements when shares are issued under certain conditions. This facilitates capital raising by listed companies that comply with continuous disclosure obligations and have no excluded information. By relying on this provision, Echo IQ issued 1.5 million shares to option holders exercising unlisted options without needing to lodge a prospectus with ASIC.

This framework acknowledges that listed companies are subject to continuous disclosure under ASX Listing Rules and the Corporations Act, providing investors with substantial public information. The Section 708A cleansing notice transparently confirms to the market that the issuance met all legal requirements and that Echo IQ’s disclosure record is current.

Unlisted Options as Employee and Investor Incentives

Unlisted options are commonly used incentives aligning employees, executives, and investors with company performance. The exercised options had a $0.35 strike price and expire on 20 June 2028, granting option holders the ability to benefit if shares appreciate beyond this price. Exercising these options converts them into fully paid ordinary shares, increasing the holders’ equity stake.

This exercise signals confidence in Echo IQ’s share value and prospects, as option holders commit capital by paying the strike price. It represents a capital raise without cash outlay from the company. Option exercises by internal stakeholders indicate belief in the company’s direction. The expiry date provides a long window for option holders to evaluate company progress before exercising.

Impact on Capital Structure and Shareholder Dilution

The 1.5 million share issuance increases Echo IQ’s total shares outstanding, affecting capital structure and diluting existing shareholders’ ownership percentages unless offset by other capital measures. If the capital raised is effectively deployed to grow revenue or market share, the absolute value of holdings may rise despite dilution.

The increased share count influences financial metrics like earnings per share (EPS) and book value per share, which may compress if earnings do not increase proportionally. Conversely, successful capital utilisation and strategic growth could enhance per-share metrics over time. The impact depends on the company’s return on capital and the strategic value of option holders as shareholders.

ASX Listing and Trading of New Shares

The 1.5 million fully paid ordinary shares are now quoted on the Australian Securities Exchange (ASX), trading alongside existing shares. These shares carry the same rights and obligations and are tradable during ASX hours under normal market conditions.

Listing on the ASX provides liquidity for option holders and subsequent investors, allowing them to buy or sell shares readily. This liquidity enables portfolio adjustments in response to market or personal factors. Shares are available for immediate trading post-issuance, subject to any contractual or ASX listing restrictions.

Continuous Disclosure and Market Transparency

Echo IQ’s confirmation of compliance with Chapter 2M of the Corporations Act 2001 underscores its commitment to market transparency and investor protection. Chapter 2M mandates immediate disclosure of material information affecting securities’ price or value, ensuring equal access for all investors.

By confirming no excluded information exists as of 22 July 2026, Echo IQ assures the market that all material information has been disclosed in compliance with ASX Listing Rules and the Corporations Act. This supports investor confidence in the company’s continuous disclosure record and the legitimacy of the Section 708A cleansing notice.

Growth and Competition in the Medical Technology Sector

Echo IQ operates within the rapidly growing medical technology and digital health sectors, driven by aging populations, rising chronic disease prevalence, and healthcare digitalisation. Cardiology, Echo IQ’s specialty, is a major segment due to cardiovascular disease’s global impact. AI-driven diagnostic and decision-support tools meet clinical needs for accurate, efficient cardiac data analysis.

The competitive landscape includes established medical device companies, healthcare software providers, and AI startups. Echo IQ’s proprietary AI software is a key competitive asset. Ongoing investment in R&D, regulatory compliance, and clinical validation is critical to maintaining its market position. Option exercises by investors may reflect confidence in Echo IQ’s growth potential within this sector.

Risks and Regulatory Considerations for Investors

Medical technology companies like Echo IQ face significant regulatory, clinical, and commercial risks. Compliance with regulations varies by jurisdiction and includes software as a medical device (SaMD) classification, clinical validation, and data privacy. In Australia, Therapeutic Goods Administration (TGA) approvals may be required. Failure to secure or maintain approvals could impair commercialisation and revenue generation.

AI and machine learning components introduce additional risks as regulatory frameworks evolve globally. Data privacy and cybersecurity are critical due to sensitive cardiac patient data; breaches could cause legal, financial, and reputational harm. Clinical effectiveness and safety require ongoing validation as algorithms adapt to diverse populations and clinical knowledge advances.